Concepedia

Author

Toufik Zahaf

GlaxoSmithKline (Belgium)ORCID

Also Known As

A Schuind, Chong-Jen Yu, T Zahaf, T. Zahaf, Toufik Zahaf

55

Publications

8.5K

Citations

25

H-Index

51

Concepts

All Affiliations

GlaxoSmithKline (Belgium)GlaxoSmithKline (United States)The University of SydneyUniversidade Estadual de Campinas (UNICAMP)Hospital de Clínicas de Porto Alegre
TZ

About

Toufik Zahaf is an author at GlaxoSmithKline (Belgium) specializing in vaccination, medicine, and human papillomavirus vaccines.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

4.4K

2

Public Health

6

6

2.5K

3

Engineering

3

3

50

4

Business

1

1

13

5

Chemistry

1

1

56

Toufik Zahaf

×

29

Publications

7.8K

Citations

22

H-Index

YearCitations

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón,

The Lancet

2009

1.6K

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler,

The Lancet

2004

1.6K

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

Himal Lal, Anthony L. Cunningham, Olivier Godeaux,

New England Journal of Medicine

2015

1.4K

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Anthony L. Cunningham, Himal Lal, Martina Kovac,

New England Journal of Medicine

2016

1K

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Cosette M. Wheeler, Xavier Castellsagué, Suzanne M. Garland,

The Lancet Oncology

2011

499

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

Paulo Naud, Cecília Roteli-Martins, Newton Sérgio de Carvalho,

Human Vaccines & Immunotherapeutics

2014

245

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

Cecília Roteli-Martins, Paulo Naud, P. De Borba,

Human Vaccines & Immunotherapeutics

2012

188

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

N. De Carvalho, Júlio César Teixeira, Cecília Roteli-Martins,

Vaccine

2010

169

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

Tino F. Schwarz, Marek Spaczyński, Achim Schneider,

Vaccine

2008

152

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

Anne Szarewski, W.A.J. Poppe, S. Rachel Skinner,

International Journal of Cancer

2011

138

Page 1